Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CDC-MMAE
- Development stage
- Preclinical
- Lead developer
- Var2 Pharmaceuticals
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CDC-MMAE is a non-targeting control drug conjugate (CDC) used in preclinical oncology research to evaluate the specificity and therapeutic index of antibody-drug conjugates (ADCs). It consists of an irrelevant protein scaffold, specifically an albumin-binding domain (ABD) fusion protein, conjugated to the cytotoxic payload monomethyl auristatin E (MMAE) via a cathepsin-cleavable valine-citrulline (vc) linker. In studies involving Vartumab-based ADCs, CDC-MMAE serves as a negative control to distinguish between target-mediated anti-tumor activity and non-specific toxicity or bystander effects. It typically features a drug-to-antibody ratio (DAR) of approximately 1.9 and is used to validate that the efficacy of targeted ADCs is driven by specific binding to antigens like oncofetal chondroitin sulfate (ofCS).
- Other names
- control drug conjugate-MMAE
02
Targets
ofCS (Oncofetal chondroitin sulfate)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on CDC-MMAE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDC-MMAE.